Trial Profile
A Phase I, Multicentre, Open-label, Self-control Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs FRSW 107 (Primary) ; Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacokinetics
- Sponsors Kaifeng Pharmaceutical
- 07 May 2020 Planned End Date changed from 31 Oct 2019 to 31 May 2020.
- 07 May 2020 Planned primary completion date changed from 31 Oct 2019 to 31 May 2020.
- 07 May 2020 Status changed from recruiting to active, no longer recruiting.